Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alvimopan (Adolor/GlaxoSmithKline).

Ijeoma A Azodo1, Eli D Ehrenpreis

  • 1University of Chicago, Department of Medicine, IL 60637, USA.

Current Opinion in Investigational Drugs (London, England : 2000)
|November 15, 2002
PubMed
Summary

Alvimopan is a peripherally active mu-opioid receptor antagonist. It is being developed to treat post-operative ileus and opioid bowel dysfunction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patients with Newly Diagnosed Cervical Cancer Should Be Screened for Anal Human Papillomavirus (HPV) and Anal Dysplasia: Results of Cost and Quality Analysis.

Pathogens (Basel, Switzerland)·2025
Same author

Tolerability and safety of a new oral device for prevention and treatment of oral mucositis in patients with hematologic malignancies undergoing chemotherapy.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2025
Same author

Pembrolizumab-Induced Duodenitis Mimicking Celiac Disease.

ACG case reports journal·2025
Same author

What Gastroenterologists Should Know About Microplastics and Nanoplastics.

Journal of clinical gastroenterology·2025
Same author

Molecular Tumor Testing on Colorectal Adenocarcinoma Specimens in a Large Community-Based Healthcare System.

Journal of patient-centered research and reviews·2024
Same author

Emerging pharmacotherapy trends in preventing and managing oral mucositis induced by chemoradiotherapy and targeted agents.

Expert opinion on pharmacotherapy·2024

Area of Science:

  • Pharmacology
  • Gastroenterology

Background:

  • Opioid medications can cause gastrointestinal side effects, including post-operative ileus (POI) and opioid bowel dysfunction (OBD).
  • Current treatments for these conditions are limited.

Purpose of the Study:

  • To evaluate alvimopan as a potential treatment for POI and OBD.
  • To assess the safety and efficacy of alvimopan in patients experiencing opioid-induced gastrointestinal dysfunction.

Main Methods:

  • Alvimopan, a peripherally acting mu-opioid receptor antagonist, was developed.
  • Clinical trials were conducted to assess its efficacy and safety.

Main Results:

  • Alvimopan demonstrated potential in treating POI and OBD.
  • Further research is ongoing to establish its therapeutic role.

Conclusions:

  • Alvimopan represents a promising therapeutic candidate for managing opioid-induced gastrointestinal complications.
  • Its peripherally selective action may offer an improved safety profile compared to centrally acting agents.

Related Experiment Videos